Effect of aniracetam on phospatidylinositol transfer protein alpha in cytosolic and plasma membrane fractions of astrocytes subjected to simulated ischemia in vitro

Pharmacological Reports

Volumn 57, Issue 5, 2005, Pages 664-669

  Gabryel, Bozena ^a   Chalimoniuk, Małgorzata ^b   Małecki, Andrzej ^a   Strosznajder, Joanna B ^b  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

Author keywords

Aniracetam; Astrocytes; Ischemia; Phosphatidylinositol transfer protein

Indexed keywords

ANIRACETAM; ISOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL TRANSFER PROTEIN ALPHA; PHOSPHOLIPID TRANSFER PROTEIN; UNCLASSIFIED DRUG; 2 PYRROLIDONE DERIVATIVE; NOOTROPIC AGENT;

ANIMAL CELL; ARTICLE; ASTROCYTE; BRAIN ISCHEMIA; CELL FRACTIONATION; CELL MEMBRANE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSOL; DISEASE SIMULATION; DRUG MECHANISM; ENZYME ACTIVATION; IN VITRO STUDY; NEWBORN; NONHUMAN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; STATISTICAL SIGNIFICANCE; ANIMAL; BIOSYNTHESIS; CELL CULTURE; DRUG EFFECT; METABOLISM; POLYACRYLAMIDE GEL ELECTROPHORESIS; WESTERN BLOTTING; WISTAR RAT;

ANIMALS; ASTROCYTES; BLOTTING, WESTERN; BRAIN ISCHEMIA; CELL MEMBRANE; CELLS, CULTURED; CYTOSOL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; NOOTROPIC AGENTS; PHOSPHOLIPID TRANSFER PROTEINS; PYRROLIDINONES; RATS; RATS, WISTAR;

EID: 33646195082     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Alb JG Jr., Cortese JD, Phillips SE, Albin RL, Nagy TR, Hamilton BA, Bankaitis VA: Mice lacking phosphatidylinositol transfer protein-alpha exhibit spinocerebellar degeneration, intestinal and hepatic steatosis, and hypoglycemia. J Biol Chem, 2003, 29, 33501-33518.
2. Alb JG Jr., Phillips SE, Rostand K, Cui X, Pinxteren J, Cotlin L, Manning T et al.: Genetic ablation of phosphatidylinositol transfer protein function in murine embryonic stem cells. Mol Biol Cell, 2002, 13, 739-754.
3. Bradford MM: A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein dye-binding. Anal Biochem, 1976, 72, 248-251.
4. Fallarino F, Genazzani AA, Silla S, L'Episcopo MR, Camici O, Corazzi L, Nicoletti F, Fioretti MC: [3H]aniracetam binds to specific recognition sites in brain membranes. J Neurochem, 1995, 65, 912-918.
5. Gabryel B, Łabuzek K, Małecki A, Herman ZS: Immunophilin ligands decrease release of pro-inflammatory cytokines (IL-1β, TNF-α and IL-2) in rat astrocyte cultures exposed to simulated ischemia in vitro. Pol J Pharmacol, 2004, 56, 129-136.
6. Gabryel B, Pudelko A, Malecki A: Erk1/2 and Akt kinases are involved in the protective effect of aniracetam in astrocytes subjected to simulated ischemia in vitro. Eur J Pharmacol, 2004, 494, 111-120.
7. Hertz L, Juurlink BHJ, Szuchet S: Cell cultures. In: Handbook of Neurochemistry. Ed. Lajtha A, Plenum Press, New York, 1985, Vol. 8, 603-661.
8. Jiang Z, Zuang Y, Chen X, Lam PY, Yang H, Xu Q, Yu ACH: Activation of Erk1/2 and Akt in astrocytes under ischemia. Biochem Biophys Res Commun, 2002, 294, 726-733.
9. Kauffmann ZA, Thomas GM, Ball A, Prosser S, Cunningham E, Cockcroft S, Hsuan JJ: Requirement for phosphatidylinositol transfer protein in epidermal growth factor signaling. Science, 1995, 268, 1188-1190.
10. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature, 1970, 227, 680-685.
11. Lucchi L, Pascale A, Battaini F, Govoni S, Trabucchi M: Cognition stimulating drugs modulate protein kinase C activity in cerebral cortex and hippocampus of adult rats. Life Sci, 1993, 53, 1821-1832.
12. Martin JR, Haefely WE: Pharmacology of aniracetam: a novel pyrrolidinone derivative with cognitive enhancing activity. Drug Invest, 1993, 5, 4-49.
13. Otomo E, Hirai S, Terashi A, Hasegawa K, Tazaki Y, Araki G, Itoh E et al.: Clinical usefulness of aniracetam for psychiatric symptoms in patients with cerebrovascular disorders: double-blind trial placebo. J Clin Exp Med, 1991, 156, 143-187.
14. Pizzi M, Fallacara C, Arrigi V, Memo M, Spano P-F: Attenuation of excitatory amino acid toxicity by metabotropic glutamate receptor agonists and aniracetam in primary cultures of cerebellar granule cells. J Neurochem, 1993, 61, 683-689.
15. Shirane M, Nakamura K: Aniracetam enhances cortical dopamine and serotonin release via cholinergic and glutamatergic mechanisms in SHRSP. Brain Res, 2001, 916, 211-221.
16. Snoek GT, Berrie CP, Geijtenbeek TB, van der Helm HA, Cadee JA, Iurisci C, Corda D, Wirtz KW: Overexpression of phosphatidylinositol transfer protein alpha in NIH3T3 cells activates a phospholipase A. J Biol Chem, 1999, 274, 35393-35399.
17. Thomas GM, Cunningham E, Fensome A, Ball A, Totty NF, Truong O, Hsuan JJ, Cockcroft S: An essential role for phosphatidylinositol transfer protein in phospholipase C-mediated inositol lipid signaling. Cell, 1993, 74, 919-928.
18. Tsuzuki K, Takeuchi T, Ozawa S: Agonist-dependent and subunit-dependent potentiation of glutamate receptors by nootropic drug aniracetam. Mol Brain Res, 1992, 16, 105-110.
19. Vuletic S, Jin LW, Marcovina SM, Peskind ER, Moller T, Albers JJ: Widespread distribution of PLTP in human CNS: evidence for PLTP synthesis by glia and neurons, and increased levels in Alzheimer's disease. J Lipid Res, 2003, 44, 1113-1123.